Natalizumab Drug Aliquot | Alpha-4 integrin | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Natalizumab are now available as research consumables.

Natalizumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Natalizumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Tysabri® / Natalizumab Reference Product

Drug nameTysabri®
INNNatalizumab
API typeNatalizumab is a recombinant humanised anti-α4-integrin antibody produced in a murine cell line by recombinant DNA technology.
Pharmacotherapeutic group
Immunosuppressants, selective immunosuppressants.
ATC code
L04AA23
Target of antibody
α4-integrin
General functionTysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (RRMS).
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Natalizumab blocks the interaction of α4β7 integrin with the mucosal addressin cell adhesion molecule-1 (MadCAM-1). Disruption of these molecular interactions prevents transmigration of mononuclear leukocytes across the endothelium into inflamed parenchymal tissue. A further mechanism of action of natalizumab may be to suppress ongoing inflammatory reactions in diseased tissues by inhibiting the interaction of α4-expressing leukocytes with their ligands in the extracellular matrix and on parenchymal cells. As such,
natalizumab may act to suppress inflammatory activity present at the disease site, and inhibit further recruitment of immune cells into inflamed tissues.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Natalizumab is a selective adhesion-molecule inhibitor and binds to the α4-subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils.
Specifically, natalizumab binds to the α4β1 integrin, blocking the interaction with its cognate receptor, vascular cell adhesion molecule-1 (VCAM-1), and ligands osteopontin, and an alternatively spliced domain of fibronectin, connecting segment-1 (CS-1).
Original license holder
Biogen Netherlands B.V.
Marketing authorisation numbers
EU/1/06/346/001
Marketing authorisation holder
Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands
Name of the manufacturer of the biological active substance
Biogen Inc
5000 Davis Drive
Research Triangle Park
NC 27709-4627
USA

FUJIFILM Diosynth Biotechnologies Denmark ApS
Biotek Allé 1
DK-3400 Hillerød
Denmark
Name and address of the manufacturer(s) responsible for batch releaseFUJIFILM Diosynth Biotechnologies Denmark ApS
Biotek Allé 1
DK-3400 Hillerød
Denmark

Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands
Max shelf life
2 years
Storage conditions
2°C – 8°C
List of excipients
Sodium phosphate, monobasic, monohydrate
Sodium phosphate, dibasic, heptahydrate
Sodium chloride
Polysorbate 80 (E 433)
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting